Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma

International Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 813-819

  Pham Nguyen, Khiem B ^a   Yang, Wen ^a   Saxena, Romil ^a   Thung, Swan N ^a   Woo, Savio L C ^a   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; IMMUNE RESPONSE; INTRATUMORAL DRUG ADMINISTRATION; LIVER CARCINOMA; LIVER METASTASIS; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE THERAPY; IMMUNITY, CELLULAR; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, NUDE; SURVIVAL RATE; T-LYMPHOCYTES; TIME;

EID: 0032962942     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO;2-I     Document Type: Article

References (33)

1. ANGIOLILLO, A.L., SGADARI, C. and TOSATO, G., A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann. N.Y. Acad. Sci., 795, 158-167 (1996).
2. BANKS, R.E., PATEL, P.M. and SELBY, P.J., Interleukin 12: a new clinical player in cytokine therapy. Brit. J. Cancer, 71, 655-659 (1995).
3. BRADLEY, L.M., DALTON, D.K. and CROFT, M., A direct role for IFN-gamma in regulation of Th1 cell development. J. Immunol., 157, 1350-1358 (1996).
4. BRUNDA, M.J., Interleukin-12. J. Leukocyte Biol., 55, 280-288 (1994).
5. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R., HUBBARD, B.R., MURPHY, M., WOLF, S.F. and GATELY, M.K., Anti-tumor and antimetastatic activity of interleukin 12 against murine tumors. J. exp. Med., 178, 1223-1230 (1993).
6. CARUSO, M., PHAM-NGUYEN, K., KWONG, Y.L., XU, B., KOSAI, K.I., FINEGOLD, M., WOO, S.L.C. and CHEN, S.H., Adenovirus-mediated interleukin-12 gene therapy for metaslatic colon carcinoma. Proc. nat. Acad. Sci. (Wash.), 93, 11302-11306 (1996).
7. CESANO, C., VISONNEAU, S., CLARK, S.C. and SANTOLI, D., Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxicity cells by IL-12. J. Immunol., 154, 2943-2957 (1993).
8. CHEN, L., CHEN, D., BLOCK, E., O'DONNELL, M., KUFE, D.W. and CLINTON, S.K., Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J. Immunol., 159, 351-359 (1997).
9. COLOMBO, M.P., VAGLINAI, M., SPREAFICO, F., PARENZA, M., CHIODONI, C., MELANI, C. and STOPPACCIARO, A., Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 56, 2531-2534 (1996).
10. CORBETT, T.H., GRISWOLD, D.P., ROBERTS, B.J., PECKHAM, J.C. and SCHABEL, F.M., Jr., Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35, 2434-2439 (1975).
11. COUGHLIN, C., WYSOCKA, M., TRINCHIERI, G. and LEE, W.M.F., The effect of interleukin 12 desensitization on the anti-tumor efficacy of recombinant interleukin 12. Cancer Res., 57, 2460-2467 (1997).
12. CUI, J., SHIN, T., KAWANO, T., SATO, H., KONDO, E., TOURA, I., KANEKO, Y., KOSEKI, H., KANNO, M. and TANIGUCHI, M., Requirement for Valpha14 NKT cells in IL-12 mediated rejection of tumor. Science, 278, 1623-1626 (1997).
13. GRAUBERT, T.A. and LEY, T.J., How do lymphocytes kill tumor cells? Clin. Cancer Res., 2, 785-789 (1996).
14. HASHIMOTO, W., TAKEDA, K., ANZAI, R., OGASAWARA, K., SAKIHARA, H., SUGIURA, K., SEKI, S. and KUMAGAI, K., Cytotoxic NK1.1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol., 154, 4333-4340 (1995).
15. KARRE, K., Express yourself or die: peptides, MHC molecules, and NK cells. Science, 267, 978-979 (1995).
16. KAWANO, T., CUI, J., KOEZUKA, Y., TOURA, I., KANEKO, Y., SATA, H., KONDO, E., HARADA, M., KOSEKI, H., NAKAYAMA, T., TANAKA, Y. and TANIGUCHI, M., Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. nat. Acad. Sci. (Wash.), 95, 5690-5693 (1998).
17. KOCH, F., STANZL, U., JENNEWEIN, P., JANKE, K., HEUFLER, C., KAMPGEN, E., ROMANI, N. and SCHULER, G., High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. exp. Med., 184, 741-746 (1996).
18. LU, L., WOO, J., LI, Y., RAO, A.S. and THOMSON, A. W., Isolation of dendritic leukocytes from mouse liver. Fund. clin. Immunol., 2, 543-547 (1995).
19. NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNICK, M.A., BRUNDA, M.J., GATELY, M., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J. and LOTZE, M.T., Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol., 154, 1697-1706 (1994).
20. NISHIMURA, T., WATANABE, K., LEE, U., YAHATA, T., KOBAYASHI, M., HERRMANN, S.H. and HABU, S., Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cells. Immunol. Lett., 48, 167-174 (1995).
21. ROBERTSON, M.J. and RITZ, J., Biological and clinical relevance of human natural killer cells. Blood, 76, 2421-2438 (1990).
22. SCOTT, P., IL-12: initiation cytokine for cell-mediated immunity. Science, 260, 496-497 (1993).
23. SGADARI, C., ANGIOLILLO, A.L. and TOSATO, G., Inhibition of angiogenesis by interleukin-12 is mediated by interferon-inducible protein 10. Blood, 87, 3877-3882 (1996).
24. SIDERS, W.M., WRIGHT, P.W., HIXON, J.A., ALVORD, W.G., BACK, T.C., WILTROUT, R.H. and FENTON, R.G., T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J. Immunol., 160, 5465-5474 (1998).
25. TAHARA, H. and LOTZE, M.T., Anti-tumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther., 2, 96-106 (1995).
26. + cells and evidence of usage of T and NK cell receptors. Transplantation, 58, 496-504 (1994).
27. + αb T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol., 156, 3366-3373 (1996).
28. TALMADGE, J.E., HERBERMAN, R.B., CHIRIGOS, M.A., MALUISHI, A.E., SCHNEIDER, M.A., ADAMS, J.S., PHILIPS, H., THURMAN, G.B., VARESIO, L., LONG, C., OLDHAM, R.K. and WILTROUT, R.H., Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators includ-ing recombinant interferons and interleukin 2. J. Immunol., 135, 2483-2491 (1985).
29. TANNENBAUM, C.S., WICKER, N., ARMSTRONG, D., TUBBS, R., FINKE, J., BUKOWSKI, R.M. and HAMILTON, T.A., Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol., 156, 693-699 (1996).
30. TSUNG, K., MEKO, J.B., PEPLINSKI, G.R., TSUNG, Y.L. and NORTON, J.A., IL-12 induces T helper 1-directed anti-tumor response. J. Immunol., 158, 3359-3365 (1997).
31. WHITESIDE, T.L. and HERBERMAN, R.B., The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol., 7, 704-710 (1995).
32. WIGGINTON, J.M., KUHNS, D.B., BACK, T.C., BRUNDA, M.J., WILTROUT, R.H. and COX, G.W., Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the anti-tumor activity of interleukin 12 and/or interleukin 2. Cancer Res., 56, 1131-1136 (1996).
33. ZATLOUKAL, K. and 12 OTHERS, Elicitation of a systemic and protective anti-melanoma immune response by an IL-12-based vaccine. J. Immunol., 14, 3406-3419 (1995).